User:Jbmontgomery24/sandbox


 * Bulleted list item

The Five Pillars of Wikipedia
1. It is an online encyclopedia.
 * Wikipedia is not a place for advertisement or opinions.
 * Since Wikipedia is an online encyclopedia, it does not mean it is a dictionary, a list of documents, or a newspaper article.

2. This site has balanced viewpoints.
 * Select articles and journals that demonstrate unbiased points of view in order to explain the key points of the topic.
 * Do not make debates on the topics. This site is not based on promoting the information; just simply state the facts with accurate sources that are properly cited.
 * If there are several viewpoints, do not state that there is one point of view that is superior to all the others.

3. The content is free on Wikipedia 4. Interaction among the editors should be done in a polite and amicable fashion.
 * This means that no one owns this site and anyone can feel free to edit, change, and use this information; however, this site is not meant for plagiarism of sources on topics.
 * Do not disrespect the copyright laws. If the content is not free, it can be used impartially.  However, it may be best to use media and content that is free to use.
 * All the contributed content maybe edited or reorganized since it is free to the public and no particular editor owns the sources (i.e. articles, journals).
 * Disagreements may arise, and in this case, respect the other Wikipedians.
 * Do not personally attack others. Remember that proper etiquette is imperative.
 * Do not be disorderly or cause combative issues towards the site to prove your views.
 * Please be open-minded and receptive to new ideas from other Wikipedians.
 * When disagreements occur, discuss them on the talk page to arise to a solution.

5. This site has flexible rules.
 * The rules tend to change over time.
 * Sometimes there maybe an exception to a rule in order to better the spirit and values of Wikipedia.
 * Mistakes are inevitable, so be brave on updating other Wikipedians' pages. All pages are saved, so the errors are easily accessible to correct if needed.

Summary of Characteristics of Target Article
Our target article is a B to GA (good article) status level.

GA (good article) criteria:
 * ~The article is well-written, meaning correct grammar usage, follows copyright guidelines, and easy to follow
 * ~Manual of style guidelines (i.e. lead section, etc.) are followed closely
 * ~No original research is used
 * ~Follows the scientific guidelines
 * ~References with inline citations, which are reliable sources (verifiable)
 * ~Main elements of the topic are enclosed in the article, where the topic is concise
 * ~Viewpoints of the topics are neutral
 * ~Editing is kept at a steady pace
 * ~When feasible, provide appropriate images that are properly cited and add substance to the topic

B article criteria:
 * ~References with inline citations, which are deemed as reliable sources (verifiable)
 * ~Topic is relatively disclosed within the article
 * ~Very few incorrect statements about the topic
 * ~Expansion on topic may be necessary but most of the important topics are included, only minor topics are absent
 * ~Cohesiveness to the article's structure (lead section and other information related to topic in an orderly fashion)
 * ~Lack of grammar errors and flows well
 * ~Manual of style guidelines are more relaxed
 * ~Supportive material when needed (i.e. illustrations - not required, though, infobox, or diagrams)
 * ~Make the article comprehensible for a wide-ranging audience

Drug Therapies for Breast Cancer Patients
Treatment for breast cancer has predominately been the use of different types of chemotherapy for numerous years; however, the last twenty years has been more focused on treating a specific target of the cancer. One of the specific treatments, aside from chemotherapy, is to treat the HER signaling pathway since there are approximately 20% of breast cancer incidents with an overexpression in the oncogene of the human epidermal growth factor 2 (HER 2). For drug therapy purposes, a monoclonal antibody trastuzumab can inhibit the production of the tumor cells that overexpress HER 2 by binding to the HER 2/neu receptors, so trastuzumab is commonly used to treat patients with metastatic disease or with a combination of chemotherapy to treat the early stages of the disease. Like all drug therapies, there can be drawbacks, which is the case for the usage of trastuzumab. For those patients receiving chemotherapy in addition to trastuzumab for the HER 2 overexpression are at a higher risk of cardiac dysfunction, but the damage to the left ventricle caused by the treatment of trastuzumab can be reversible if detected early on.

Explanation of References for Unit 7
~ Define and distinguish direct and indirect approaches on this technique - reference #1

~ Explain antibody binding and specificity - reference #1
 * This study has a nice explanation on primary and secondary antibodies of different species and how they react to one another. Also, it has some nice examples of direct and indirect approaches.

~Explain antibody binding and specificity - reference #2
 * This study uses the fibrillarin-GFP expressed cells, which were immunolabeled with antibodies to fibrillarin. I thought it demonstrated a nice inverse relationship between a strong or weak signal in regards to the intensity stain of the nucleus of the cells.

~ Immunolabeling for Electron Microscopy (i.e., labeling chromosome structure) - reference #3
 * This study explains how immunolabeling is incorporated into the chromosome structure and viewed via EM.

~ Immunolabeling for Electron Microscopy (i.e., labeling chromosome structure)- reference #4

~ Immunolabeling with gold (Immunogold labeling) - reference #4


 * Reference #4 give a little a history of EM and colloidal gold in regards to immunolabeling on pg. 404.

~ Immunolabeling for Scanning Electron Microscopy (SEM)- reference #5

~ Immunolabeling with gold (Immunogold labeling) - reference #5
 * This book gives a nice overview of SEM and Immunogold labeling - straightforward explanation

~ Immunolabeling with gold (Immunogold labeling) - reference #6
 * The Lodish, H., et al. text gives a nice explanation and visual of how a gold particle binds to the Fc domain of the antibody with the corresponding antigen and the a protein of interest. The book is explaining a transmission electron microscopy (TEM) example, but I thought the concept was explained well despite it being the TEM method.

Immunolabeling Outline
I.  Modify the current lead section - add references, inline citations, and generalize the terminology for better understanding for any audience
 * i.  Define immunolabeling and distinguish it from immunocytochemistry and immunohistochemistry
 * ii. Explain the kinds of information that can be obtained through this technique
 * iii. Distinguish the direct and indirect approaches to immunolabeling and thereby introduce and define the primary and seondary antibodies and their attributes.
 * iv. Include a cartoon to the upper right to immediately show the essence of the more common, indirect procedure
 * v.  Explain some of the more common tags, the advantages and disadvantages of each

II. History and background on immunolabeling
 * i. Scientists behind this groundbreaking technique
 * ii. The timeline of tag devlopment and the means of visualization

III. Explain what kind of information can be obtained via immunolabeling. This can accompanied with examples of actual photographs demonstrating the power of immunocytochemistry and immnohistochemistry.

IV. Define and distinguish direct and indirect approaches on this technique.
 * i. Indirect approach
 * ii. Direct approach

V.  Explain antibody binding and specificity.
 * i. Explain how primary and secondary antibodies are made.

VI. Explain the nature of the tags.

VII. Explain how the tag information is collected and resolved.

VII. Examples of specific immunolabaling methods
 * i. Immunolabeling for Electron Microscopy (i.e., labeling chromosome structure)
 * ii. Immunolabeling for Scanning Electron Microscopy (SEM)
 * iii. Immunolabeling with gold (Immunogold labeling)

Images
Immunolabeling - Wikimedia Commons